Clinical Trial

A Study of LAD191 in Adults With Hidradenitis Suppurativa

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to assess the efficacy of multiple dosing regimens of LAD191 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS) and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-02; most recent amendment 2026-05-07.
Status change: Not Yet Recruiting → Recruiting 2026-05-07
Trial Details
NCT Number NCT07151937
Lead Sponsor Almirall, S.A.
Conditions Hidradenitis Suppurativa
Enrollment 200 participants
Start Date 2025-11-05
Primary Completion 2027-05-25 (estimated)
Study Completion 2027-11-25 (estimated)
Updated on ClinicalTrials.gov 2026-05-11